Abstract

The renaissance in the use of peptides and proteins as therapeutic agents has led to significant demand for new technologies to rapidly and efficiently access these biomolecules, especially those bearing tailor-made modifications to maximize specificity and activity, or to probe biological function (e.g. through incorporation of post-translational modifications, fluorophores and/or imaging reagents).1 We have recently developed a number of synthetic and semi-synthetic technologies that enable efficient production of peptides and proteins with homogeneous post-translational modifications at pre-determined sites.2,3 This talk will highlight the utility of these technologies for: (1) manufacturing peptidic drugs under continuous flow conditions,3 and (2) generating proteins with site-specific and homogeneous post-translational modifications.4-6 The talk will conclude with our efforts to employ peptide display methods with genetic reprogramming to generate high affinity cyclic peptides for a range of therapeutic targets.7-9

References

1 S. Kulkarni et al. Nature Rev. Chem. 2018, 2, 0122. 2 S. Kulkarni et al. Nature Protocols, 2019, 14, 2229. 3 T. Chisholm et al. J. Am. Chem. Soc. 2020, 142, 1090 4 B. Premdjee et al. J. Am. Chem. Soc. 2021, 143, 5336 5 S. Kulkarni et al. Angew. Chem. Int. Ed. 2022, 61, e202200163 6 L. Dowman et al. Nature Commun. 2022, 13, 6885. 7 J. Johansen-Leete et al. J. Am. Chem. Soc. 2020, 142, 9141 8 J. Johansen-Leete et al. Chem. Sci. 2022, 13, 3826 9 A. Norman et al. ACS Cent. Sci. 2021, 7, 1001